EMB-07 / EpimAb Biotherap - LARVOL DELTA

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=115 | Recruiting | Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release (AACR 2024) - P1 | "This study supports the clinical development of EMB-07 for treating multiple solid tumors with ROR1 expression. A FIH study of EMB-07 in locally advanced/metastatic solid tumors or relapse/refractory lymphoma is currently ongoing (NCT05607498)."

Bispecific • IO biomarker • Late-breaking abstract • Breast Cancer • Endometrial Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Adenocarcinoma • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • ROR1

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=115 | Not yet recruiting | Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.

New P1/2 trial • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

EpimAb Biotherapeutics to Present Late-breaking Abstract on Preclinical Results of EMB-07 at the 2024 American Association for Cancer Research Annual Meeting (Businesswire) - "EpimAb Biotherapeutics...is pleased to announce the acceptance of a late-breaking abstract featuring our novel T-cell engager (TCE) EMB-07 as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting....This presentation will highlight the preclinical results for EMB-07, a novel ROR1 targeting TCE designed with an optimized efficacy, safety and pharmacokinetic profile. Furthermore, the presentation will discuss the TCE’s differentiated in vitro potency relative to benchmark molecules constructed using different modalities."

Late-breaking abstract • Preclinical • Oncology

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd. | N=75 ➔ 150 | Trial completion date: Jul 2025 ➔ Mar 2026 | Trial primary completion date: Mar 2025 ➔ Oct 2025

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Chronic Lymphocytic Leukemia • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Adenocarcinoma • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2022 ➔ Feb 2023

Enrollment open • Metastases • Trial initiation date • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=75 | Not yet recruiting | Sponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd.

New P1 trial • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer